THE ÓSKARE CAPITAL TEAM
Over 100 years of combined experience in venture capital, business building, science and intellectual property, and bringing medicines and products to market.
DR. ZSOLT LENKEI MD, PHD
Medical doctor and neuroscientist, and one of the leading experts in the functioning of the… read more
Seasoned Investment Advisor focused on the global supply chain of cannabis. Built a portfolio of… read more
Alexandre OUIMET- STORRS B.ENG, M.SC
Chemical engineer (B.Eng/M.Sc) with 9 years of Venture Capital experience in Deeptech and Corporate VC
Experienced in early stage investment and incubation
Performed more than 15 investments and 40 transactions (over 100 MEUR invested)
Track record: 2.2 X and 15% IRR
Independent board member, angel investor and lecturer at Paristech
JOHN D ROGERS, MD, MPH
American trained clinical Neurologist with over 18 year track record in international healthcare, pharma and medical device sectors
Experienced Senior international Medical Affairs leader in Allergan and Galderma Nestlé Skin Health focusing on medical marketing strategies, data generation, publications & KOL engagement
Experienced CFO and Secretary General in 3 venture capital funds in France and US
Former auditor with several years of transaction experience
Experienced working with institutional investors and financial regulators
Significant fundraising experience (over 1 billion euros raised for funds)
NICOLA BROUGHTON BA, MBA, PHD, DIPLAW
20 year career in VC, life science and tech sectors with significant expertise in working with academic research groups, spinoffs, and early stage investments.
Investment Director (+ 5 years) with record in identifying and growing value in life science businesses, optimizing IP strategy, and licensing.
Experience as non-executive director in Life Science and Software companies
DR. ZSOLT LENKEI MD, PHD
EXPERTISE: Neuroscience, Cannabinoid receptor science, basic science research methodology, mentorship to researchers and teams.
PROFESSOR AND DIRECTOR Professor, Université Pierre et Marie Curie, Centre de Psychiatrie et Neurosciences, INSERM Research Director; Co-founder, Iconeus.
Oliver Lamb M.SC
Experienced Director and Board member for UK cannabis companies.
Experienced European cannabis and controlled environment agriculture consultant.
Machine learning market monitoring algorithm development at Morgan Stanley.
Seasoned Investment Advisor focused on the global supply chain of cannabis.
Built a portfolio of early stage, pre-IPO companies as CIO of a Family Office.
Served as Board Member and Series A co-lead for Privateer Holdings.
Head of Valuations for a Venture Capital Fund and Technology Incubator.
Graduate of the University of Wisconsin-Madison.
5+ years of Venture Capital experience focussed on European Technology companies. Held positions at Mercia Asset Management & Mobeus Equity Partners with responsibilities spanning deal origination, transactions and portfolio management.
Founder of two European cannabis businesses; Golders Hill & KXC. Successfully raised seed funding for both and exited GH to a Canadian acquirer (now trading as iuvo Therapeutics GmbH).
Founder of Bashert Capital, providing corporate finance and strategic advisory services to the global cannabis industry.
Chairman and Senior Advisors
As non-executive Chairman of ÓSKARE CAPITAL, Canadian businessman Bruce Linton provides strategic leadership and serves as head of the investment committee. Linton is a recognized leader, visionary and entrepreneur in the cannabinoid industry. In 2013 Linton co-founded Tweed, which became Canopy Growth and was the first cannabis producer to IPO on the Nasdaq in 2018 (CGC – market cap of $7 billion).
Bruce created the world’s largest diversified and integrated cannabinoid, hemp and cannabinoid derivatives company. By working closely with external Advisors, our network of investors, and with portfolio companies of ÓSKARE CAPITAL, Bruce shares his industry knowledge, network and expertise.
DR. OLIVIER BRANDICOURT
PHARMA & HEALTHCARE Executive. Former CEO of Sanofi and Bayer HealthCare AG; C-Level executive at Pfizer.
EXPERTISE: Pharmaceutical Industry, Consumer Healthcare, Strategy, Medical Affairs.
DR. MIRI HALPERIN WERNLI
Co-Founder and CEO of CRESO PHARMA. Head of Global Clinical Development, Actelion (VP Business & Scientific Affairs).
Board member MindMed.
EXPERTISE: Cannabinoids, IPOs, psychedelics, clinical trials, drug development & cannabis market.
Industry Analyst and Specialist in Beverages, Cannabis, and Consumer Goods, BRYAN GARNIER
EXPERTISE: Cannabis Markets, Financial Analysis, Food and Beverage Markets, Fundraising, Strategy